Levosert (Levonorgestrel)

Levonorgestrel released from the intrauterine system thickens cervical mucus, reduces sperm motility, and suppresses the growth of the uterine lining. In some cycles it may also inhibit ovulation, together preventing fertilisation and implantation.

Levosert is supplied as a pre‑loaded 52 mg intrauterine system. The exact dosing regimen, including insertion timing and duration of use, is determined by the prescribing clinician based on individual patient needs and regulatory guidelines.

Levosert is contraindicated in pregnancy and must not be inserted in a pregnant woman. Women who become pregnant while the device is in place should have it removed. Limited data exist for breastfeeding; clinicians should weigh benefits against potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Compared with oral or injectable progestogens, Levosert offers continuous, low‑dose hormone release directly within the uterus, eliminating daily adherence requirements. It typically provides longer protection (up to 5 years) and fewer systemic side effects than systemic hormonal methods.

Levosert should be stored at room temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures to maintain its integrity until insertion.

Levosert is inserted by a trained healthcare professional into the uterine cavity using a specialized inserter. The procedure is performed in a clinical setting under aseptic conditions, and the device remains in place for the approved duration without the need for daily dosing.

Serious risks include uterine perforation during insertion, device expulsion, pelvic inflammatory infection, and the rare possibility of ectopic pregnancy if contraceptive failure occurs. Prompt medical evaluation is required if severe abdominal pain, abnormal bleeding or signs of infection develop.

Levosert is contraindicated in women who are pregnant, have known or suspected uterine anomalies, active pelvic infection, breast cancer, or a history of thromboembolic disorders. Women with unexplained vaginal bleeding should be evaluated before insertion.